Clinical Scorecard: Phase 2b Study of Sonlicromanol in Individuals with Mitochondrial Disease Linked to the m.3243A>G Mutation
At a Glance
Category
Detail
Condition
Primary mitochondrial disease associated with the m.3243A>G mutation
Key Mechanisms
Sonlicromanol modulates reductive and oxidative distress by selectively inhibiting microsomal prostaglandin E1 synthase, improving cellular redox status, reducing lipid peroxidation, and attenuating inflammation
Target Population
Adults with primary mitochondrial disease carrying the m.3243A>G mutation
Care Setting
Clinical trial setting including randomized controlled and open-label extension studies
Key Highlights
Sonlicromanol was well tolerated with a favorable safety profile over 1 year of treatment
No statistically significant improvement in primary cognitive endpoint in overall population, but treatment effects observed in patients with more affected baseline status
Long-term treatment showed clinically meaningful improvements in mood, cognition, fatigue, pain, balance, and quality of life measures
Guideline-Based Recommendations
Diagnosis
Diagnosis based on identification of m.3243A>G mutation in patients presenting with mitochondrial disease phenotypes such as MELAS, MIDD, MP, or CPEO
Management
Sonlicromanol administered orally at 100 mg twice daily demonstrated potential benefits in symptom domains and was well tolerated
Consider long-term treatment to achieve more pronounced clinical improvements
Monitoring & Follow-up
Monitor cognitive function, mood (e.g., Beck Depression Inventory), fatigue, pain, and physical performance during treatment
Assess safety and tolerability regularly during therapy
Risks
No significant safety concerns reported in phase 2b study; favorable benefit-risk profile observed
Patient & Prescribing Data
Adults with primary mitochondrial disease harboring the m.3243A>G mutation
Sonlicromanol shows efficacy particularly in patients with more severe baseline impairment; improvements noted in cognitive, mood, fatigue, pain, and physical function domains with good tolerability
Clinical Best Practices
Select patients with confirmed m.3243A>G mutation and symptomatic mitochondrial disease for sonlicromanol therapy
Use validated patient- and clinician-reported outcome measures to evaluate treatment response
Consider extended treatment duration (up to 1 year) to maximize clinical benefits
Regularly monitor safety parameters and patient-reported symptoms to guide therapy
by Jan Smeitink, Just van Es, Brigitte Bosman, Mirian C H Janssen, Thomas Klopstock, Grainne Gorman, John Vissing, Gerrit Ruiterkamp, Chris J Edgar, Evertine J Abbink, Rob van Maanen, Oksana Pogoryelova, Claudia Stendel, Almut Bischoff, Ivan Karin, Mahtab Munshi, Anne Kümmel, Lydia Burgert, Christianne Verhaak, Herma Renkema
A new BMJ Opinion piece takes aim at a growing tendency among clinicians: translating public behavior into clinical diagnosis—especially when the subject is a political leader.
